Expression of the complement system's activation factors in plasma of patients with early/late-onset severe pre-eclampsia

American Journal of Reproductive Immunology

Volumn 76, Issue 3, 2016, Pages 205-211

  He, Yingdong ^a   Xu, Bingning ^a   Song, Di ^a,b,c   Yu, Feng ^a,b,c   Chen, Qian ^a   Zhao, Minghui ^a,b,c,d  

^a PEKING UNIVERSITY FIRST HOSPITAL   (China)

^b BEIJING HOSPITAL   (China)

^c BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^d Tsinghua University   (China)

Author keywords

alternative pathway; complement activation; pre eclampsia

Indexed keywords

COMPLEMENT; COMPLEMENT COMPONENT BB; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C4D; COMPLEMENT COMPONENT C5A; COMPLEMENT COMPONENT MAC; COMPLEMENT COMPONENT MBL; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD SAMPLING; CASE CONTROL STUDY; COMPARATIVE STUDY; COMPLEMENT ACTIVATION; CONTROLLED STUDY; EARLY ONSET SEVERE PRE ECLAMPSIA; FEMALE; GESTATIONAL AGE; HUMAN; LATE ONSET SEVERE PRE ECLAMPSIA; MAJOR CLINICAL STUDY; PATHOGENESIS; PERIPHERAL CIRCULATION; PREECLAMPSIA; PREGNANT WOMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; THROMBOCYTE COUNT;

EID: 84982141403     PISSN: 10467408     EISSN: 16000897     Source Type: Journal    
DOI: 10.1111/aji.12541     Document Type: Article

References (23)

1. Steegers EA, von Dadelszen P, Duvekot JJ, Pijnenborg R. Pre-eclampsia. Lancet. 2010;376:631–644.
2. Derzsy Z, Prohaszka Z, Rigo JJ, Fust G, Molvarec A. Activation of the complement system in normal pregnancy and preeclampsia. Mol Immunol. 2010;47:1500–1506.
3. Lokki AI, Heikkinen-Eloranta J, Jarva H, et al. Complement activation and regulation in preeclamptic placenta. Front Immunol. 2014;5:312.
4. Wang W, Irani RA, Zhang Y, et al. Autoantibody-mediated complement C3a receptor activation contributes to the pathogenesis of preeclampsia. Hypertension. 2012;60:712–721.
5. Lynch AM, Gibbs RS, Murphy JR, Giclas PC, Salmon JE, Holers VM. Early elevations of the complement activation fragment C3a and adverse pregnancy outcomes. Obstet Gynecol. 2011;117:75–83.
6. Denny KJ, Coulthard LG, Finnell RH, Callaway LK, Taylor SM, Woodruff TM. Elevated complement factor C5a in maternal and umbilical cord plasma in preeclampsia. J Reprod Immunol. 2013;97:211–216.
7. Hoffman MC, Rumer KK, Kramer A, Lynch AM, Winn VD. Maternal and fetal alternative complement pathway activation in early severe preeclampsia. Am J Reprod Immunol. 2014;71:55–60.
8. Velickovic I, Dalloul M, Wong KA, et al. Complement factor B activation in patients with preeclampsia. J Reprod Immunol. 2015;109:94–100.
9. Kilpatrick DC. Human mannan binding protein in pre-eclampsia. Immunol Lett. 1996;49:175–177.
10. Csuka D, Molvarec A, Derzsy Z, et al. Functional analysis of the mannose-binding lectin complement pathway in normal pregnancy and preeclampsia. J Reprod Immunol. 2010;87:90–96.
11. Nelson DB, Ziadie MS, McIntire DD, Rogers BB, Leveno KJ. Placental pathology suggesting that preeclampsia is more than one disease. Am J Obstet Gynecol. 2014;210:61–66.
12. Raymond D, Peterson E. A critical review of early-onset and late-onset preeclampsia. Obstet Gynecol Surv. 2011;66:497–506.
13. Roberts JM, August PA, Bakris G, et al. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists' Task Force on Hypertension in Pregnancy. Obstet Gynecol. 2013;122:1122–1131.
14. Nascimento EJ, Silva AM, Cordeiro MT, et al. Alternative complement pathway deregulation is correlated with dengue severity. PLoS One. 2009;4:e6782.
15. Förster-Waldl E, Cokoja L, Förster O, Maurer W. Mannose-binding lectin: comparison of two assays for the quantification of MBL in the serum of pediatric patients. J Immunol Methods. 2003;276:143–146.
16. Nishizawa H, Pryor-Koishi K, Kato T, Kowa H, Kurahashi H, Udagawa Y. Microarray analysis of differentially expressed fetal genes in placental tissue derived from early and late onset severe pre-eclampsia. Placenta. 2007;28:487–497.
17. Qing X, Redecha PB, Burmeister MA, et al. Targeted inhibition of complement activation prevents features of preeclampsia in mice. Kidney Int. 2011;79:331–339.
18. Burwick RM, Feinberg BB. Eculizumab for the treatment of preeclampsia/HELLP syndrome. Placenta. 2013;34:201–203.
19. Lynch AM, Murphy JR, Byers T, et al. Alternative complement pathway activation fragment Bb in early pregnancy as a predictor of preeclampsia. Am J Obstet Gynecol. 2008;198:385.e1–e9.
20. Bulla R, Agostinis C, Bossi F, et al. Decidual endothelial cells express surface-bound C1q as a molecular bridge between endovascular trophoblast and decidual endothelium. Mol Immunol. 2008;45:2629–2640.
21. Agostinis C, Bulla R, Tripodo C, et al. An alternative role of C1q in cell migration and tissue remodeling: contribution to trophoblast invasion and placental development. J Immunol. 2010;185:4420–4429.
22. Singh J, Ahmed A, Girardi G. Role of complement component C1q in the onset of preeclampsia in mice. Hypertension. 2011;58:716–724.
23. Buurma A, Cohen D, Veraar K, et al. Preeclampsia is characterized by placental complement dysregulation. Hypertension. 2012;60:1332–1337.